The CYP 2C19*2 and CYP2C19*17 polymorphisms play a vital role in platelet responsiveness to clopidogrel after percutaneous coronary intervention: a pharmacogenomic study
Künye
Saydam, F., Değirmenci, İ., Birdane, A., Özdemir, M., Ulus, T., Özbayer, C., Çolak, E., Ata, N., & Güneş, H. V. (2017). The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study. Basic & clinical pharmacology & toxicology, 121(1), 29–36. https://doi.org/10.1111/bcpt.12763Özet
Background: Clopidogrel inhibits platelet activation and aggregation by blocking the P2Y12 receptor. Dual antiplatelet therapy with
clopidogrel and aspirin is recommended treatment by current guidelines for patients undergoing percutaneous interventions.
